Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 228
- High / Low ₹ 316 / 111
- Stock P/E 41.5
- Book Value ₹ 41.3
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 5.52 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 6m | Mar 2024 | TTM | |
|---|---|---|---|
| 8.03 | 18.96 | 22.00 | |
| 7.09 | 16.59 | 18.01 | |
| Operating Profit | 0.94 | 2.37 | 3.99 |
| OPM % | 11.71% | 12.50% | 18.14% |
| 0.01 | 0.03 | 0.06 | |
| Interest | 0.00 | 0.09 | 0.10 |
| Depreciation | 0.00 | 0.01 | 0.01 |
| Profit before tax | 0.95 | 2.30 | 3.94 |
| Tax % | 26.32% | 26.09% | |
| 0.70 | 1.70 | 2.94 | |
| EPS in Rs | 2.03 | 3.47 | 6.00 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 58% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Sep 2024 | |
|---|---|---|
| Equity Capital | 4.90 | 4.90 |
| Reserves | 13.44 | 15.35 |
| 1.61 | 1.55 | |
| 0.93 | 1.37 | |
| Total Liabilities | 20.88 | 23.17 |
| 0.05 | 0.06 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.43 | 0.44 |
| 20.40 | 22.67 | |
| Total Assets | 20.88 | 23.17 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | |
|---|---|---|
| -0.81 | ||
| -3.73 | ||
| 13.13 | ||
| Net Cash Flow | 8.59 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | 90.48 | |
| Inventory Days | 6.27 | |
| Days Payable | 1.16 | |
| Cash Conversion Cycle | 95.59 | |
| Working Capital Days | 145.35 | |
| ROCE % |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 6h
- Notice Is Hereby Given For Extraordinary General Meeting Held On 16Th May, 2025 At 12:30 P.M.. 1d
-
Announcement under Regulation 30 (LODR)-Raising of Funds
17 Apr - Preferential allotment of 4 lakh convertible warrants for Rs. 10.04 crore.
-
Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD ON DATED 17Th April, 2025
17 Apr - Preferential allotment of 4 lakh convertible warrants for Rs. 10.04 crore.
-
Disclosure Under Regulation 30 Of SEBI(Listing Obligation And Disclosure Requirements), Regulation, 2015.
15 Apr - US FDA approval received for nebulizer products.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.